Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit

VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is pleased to announce participation at the 13th Annual Tumour Models Summit. The Company’s president and chief scientific officer, Prof. Mads Daugaard, has been invited as an expert speaker at the event, which will take place December 4–5, 2024, in London, UK.

Prof. Daugaard will deliver a podium presentation highlighting Rakovina Therapeutics’ research and the Company’s product development pipeline, followed by examples of various model systems used by the Company in the development of cancer therapies.

Presentation Details:

• Title: 3D Bioprinted Bone Mimics for Cancer Research & Drug Screening
  • Discussing the development of these models
  • Interrogating how these models can be used to study metastases and for drug screening
• Session: Evaluating In Vitro & Complex 3D Models for Preclinical Research
• Presentation Date: December 5, 2024
• Presentation Time: 2:30pm GMT

Prof. Daugaard has also been invited to Chair the session that follows the presentation entitled: Model Validation & Characterisation to Optimise Research Efficiency & Increase Translational Impact.

About The 13th Annual Tumour Models London Summit
The 13th Annual Tumour Models London Summit brings together leading experts from academia, industry, and clinical research to explore the latest advancements in cancer research and therapeutic development. Focused on innovative tumour models, the summit provides a platform for sharing cutting-edge insights into drug discovery, precision medicine, and overcoming the challenges of translating research into clinical outcomes. With discussions ranging from novel model systems to biomarkers and therapeutic strategies, the event reinforced the critical role of tumour models in advancing cancer treatment and improving patient outcomes. For more information, please visit: https://tumour-models.com/

About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition.

Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedarplus.ca.

For Further Information Contact:
Jeffrey Bacha, BSC, MBA
Executive Chairman and Director
info@rakovinatherapeutics.com

Investor Relations and Media:
Susan Xu
Investor Relations
IR@rakovinatherapeutics.com
778-323-0959